FOXO Technologies Secures $1.5M to Revolutionize Longevity Insurance with Cutting-Edge Epigenetic AI Solutions

FOXO Technologies is delighted to announce a successful funding round that raised $1,500,000, marking a significant milestone in our journey to revolutionize the global longevity insurance industry. As a company at the forefront of innovation, FOXO Technologies is transforming traditional underwriting practices by harnessing cutting-edge epigenetic technology. Our next-generation underwriting protocol and consumer engagement platform offer insurers an unprecedented ability to assess risk and personalize product offerings, all while empowering consumers with deeper insights into their health and aging processes. This new influx of capital will be strategically deployed to further enhance our leading supervised machine learning and artificial intelligence solutions. By investing in research and development, we aim to expand our capabilities in identifying epigenetic biomarkers that accurately measure current states of health and aging. With this investment, not only will we refine our technological framework, but we will also accelerate the integration of our advanced systems into the global insurance landscape. Our mission has always been to leverage innovation for better outcomes, and this funding milestone represents a vote of confidence in our vision and efforts from our investors. The financial support will enable us to bolster our team with top-tier talent, continue developing breakthrough technology, and extend our reach to new markets where longevity insurance is emerging as a critical necessity. We are excited for the journey ahead and remain committed to pushing the boundaries of what is possible in underwriting technology, ensuring that both consumers and insurers benefit from more precise, transparent, and forward-thinking solutions.